These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

484 related articles for article (PubMed ID: 29392440)

  • 41. Interactions between the Kynurenine and the Endocannabinoid System with Special Emphasis on Migraine.
    Nagy-Grócz G; Zádor F; Dvorácskó S; Bohár Z; Benyhe S; Tömböly C; Párdutz Á; Vécsei L
    Int J Mol Sci; 2017 Jul; 18(8):. PubMed ID: 28758944
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Distinctive Evidence Involved in the Role of Endocannabinoid Signalling in Parkinson's Disease: A Perspective on Associated Therapeutic Interventions.
    Behl T; Kaur G; Bungau S; Jhanji R; Kumar A; Mehta V; Zengin G; Brata R; Hassan SSU; Fratila O
    Int J Mol Sci; 2020 Aug; 21(17):. PubMed ID: 32872273
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cannabinoid signalling in the enteric nervous system.
    Galligan JJ
    Neurogastroenterol Motil; 2009 Sep; 21(9):899-902. PubMed ID: 19689654
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Cannabinoid system and neuroinflammation: implications for multiple sclerosis.
    Correa F; Docagne F; Mestre L; Loría F; Hernangómez M; Borrell J; Guaza C
    Neuroimmunomodulation; 2007; 14(3-4):182-7. PubMed ID: 18073512
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting the Endocannabinoid System: From the Need for New Therapies to the Development of a Promising Strategy. What About Pancreatic Cancer?
    Garmpis N; Damaskos C; Dimitroulis D; Garmpi A; Diamantis E; Sarantis P; Georgakopoulou VE; Patsouras A; Prevezanos D; Syllaios A; Kyriakos G; Koustas E; Despotidis M; Vallilas C; Papalexis P; Antoniou EA; Kontzoglou K; Kouraklis G
    In Vivo; 2022; 36(2):543-555. PubMed ID: 35241505
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia.
    Vigano D; Guidali C; Petrosino S; Realini N; Rubino T; Di Marzo V; Parolaro D
    Int J Neuropsychopharmacol; 2009 Jun; 12(5):599-614. PubMed ID: 18789179
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Human Laboratory Studies on Cannabinoids and Psychosis.
    Sherif M; Radhakrishnan R; D'Souza DC; Ranganathan M
    Biol Psychiatry; 2016 Apr; 79(7):526-38. PubMed ID: 26970363
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The Endocannabinoid System: A Target for Cancer Treatment.
    Laezza C; Pagano C; Navarra G; Pastorino O; Proto MC; Fiore D; Piscopo C; Gazzerro P; Bifulco M
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 31979368
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Alcohol and endocannabinoids: neuroendocrine interactions in the reproductive axis.
    Rettori V; De Laurentiis A; Fernandez-Solari J
    Exp Neurol; 2010 Jul; 224(1):15-22. PubMed ID: 20353777
    [TBL] [Abstract][Full Text] [Related]  

  • 50. From endocannabinoid profiling to 'endocannabinoid therapeutics'.
    Ligresti A; Petrosino S; Di Marzo V
    Curr Opin Chem Biol; 2009 Jun; 13(3):321-31. PubMed ID: 19497779
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The endocannabinoid system in normal and pathological brain ageing.
    Bilkei-Gorzo A
    Philos Trans R Soc Lond B Biol Sci; 2012 Dec; 367(1607):3326-41. PubMed ID: 23108550
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Epigenetics and the endocannabinoid system signaling: An intricate interplay modulating neurodevelopment.
    Gomes TM; Dias da Silva D; Carmo H; Carvalho F; Silva JP
    Pharmacol Res; 2020 Dec; 162():105237. PubMed ID: 33053442
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Role of endogenous cannabinoids in synaptic signaling.
    Freund TF; Katona I; Piomelli D
    Physiol Rev; 2003 Jul; 83(3):1017-66. PubMed ID: 12843414
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The Endocannabinoid System in Glial Cells and Their Profitable Interactions to Treat Epilepsy: Evidence from Animal Models.
    Egaña-Huguet J; Soria-Gómez E; Grandes P
    Int J Mol Sci; 2021 Dec; 22(24):. PubMed ID: 34948035
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Glial endocannabinoid system in pain modulation.
    Wang J
    Int J Neurosci; 2019 Jan; 129(1):94-100. PubMed ID: 30084280
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A synthetic cannabinoid, CP55940, inhibits lipopolysaccharide-induced cytokine mRNA expression in a cannabinoid receptor-independent mechanism in rat cerebellar granule cells.
    Chiba T; Ueno S; Obara Y; Nakahata N
    J Pharm Pharmacol; 2011 May; 63(5):636-47. PubMed ID: 21492165
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Focus on cannabinoids and synthetic cannabinoids.
    Le Boisselier R; Alexandre J; Lelong-Boulouard V; Debruyne D
    Clin Pharmacol Ther; 2017 Feb; 101(2):220-229. PubMed ID: 27861784
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Seeing over the horizon - targeting the endocannabinoid system for the treatment of ocular disease.
    Cairns EA; Toguri JT; Porter RF; Szczesniak AM; Kelly ME
    J Basic Clin Physiol Pharmacol; 2016 May; 27(3):253-65. PubMed ID: 26565550
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cannabinoids and the immune system: an overview.
    Tanasescu R; Constantinescu CS
    Immunobiology; 2010 Aug; 215(8):588-97. PubMed ID: 20153077
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Decreased glial reactivity could be involved in the antipsychotic-like effect of cannabidiol.
    Gomes FV; Llorente R; Del Bel EA; Viveros MP; López-Gallardo M; Guimarães FS
    Schizophr Res; 2015 May; 164(1-3):155-63. PubMed ID: 25680767
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.